-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After being rejected by the National Institute of Health and Care Excellence (NICE), Johnson & Johnson’s Erleada drug has recently regained NICE’s positive opinion.
In May 2021, NICE issued a draft guideline.
The current standard treatment for hormone-relapsed non-metastatic prostate cancer is ADT alone or together with darolutamide (another androgen receptor inhibitor)
At the time, NICE attributed this uncertainty to the special circumstances of the patients in the trial
NICE said in a statement that it will use a clinical framework based on personal risk to identify patients who are not suitable and cannot tolerate docetaxel
As a follow-up product of Johnson & Johnson's prostate treatment Zytiga, Erleada is a new type of non-steroidal androgen receptor (AR) inhibitor, which can block the action of androgens, thereby inhibiting tumor growth
A series of successful regulatory results for the drug are supported by data from Phase III trials
In China, Erleada also received accelerated approval in September 2019 for the treatment of adult patients with nmCRPC who are at high risk of metastasis.
Reference source:
Reference source:1.
1.
2.
Another discount does the trick: Johnson & Johnson wins NICE backing for prostate cancer drug Erleada